ストックスクリーナーアプリを入手
15.63
3.03%
0.46
アフターアワーズ：
15.85
0.22
+1.41%
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm
Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (SWB:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (DUS:C17) - TradingView
CRVS Forecast — Price Target — Prediction for 2027 - TradingView
Corvus Pharmaceuticals (CRVS) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - Yahoo Finance
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock - simplywall.st
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corvus CEO thinks his next blockbuster is an ITK inhibitor - Pharma Voice
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Stockholders Approve Directors and Governance Proposals - TipRanks
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Corvus Hikes on Position in Angel - Baystreet.ca
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - The Manila Times
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
CRVS: Soquelitinib progresses in pivotal trials for PTCL and AD, targeting broad immunology markets - TradingView
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Corvus drops after early-stage trial data for eczema therapy - MSN
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - simplywall.st
CRVSCorvus Pharmaceuticals Inc Latest SEC Filings - Finviz
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):